AstraZeneca had had high hopes for the MYSTIC immunotherapy trial.
Phil Noble/ REUTERS
By Reuters
August 24, 2016

Pharmaceutical company AstraZeneca (azncf) said it had agreed to sell its small molecule antibiotics business to Pfizer (pfe) in a deal that could reach more than $1.5 billion.

The portfolio includes approved antibiotics Merrem, Zinforo and Zavicefta, and ATM-AVI and CXL, which are in clinical development, it said.

Pfizer will pay $550 million upon completion and a further unconditional $175 million in January 2019, AstraZeneca said, plus up to $250 million in milestones, up to $600 million in sales-related payments and recurring, double-digit royalties on future sales of Zavicefta and ATM-AVI in certain markets.

Subscribe to Term Sheet, Fortune’s daily email about deals and deal-makers.

For more on Pfizer, watch Fortune’s video:

The British company said the agreement did not impact its financial guidance for 2016.


You May Like